SCHEMBL15601829

SCHEMBL15601829

Cc1cnn(Cc2cccc(C(=O)NC(C)C(=O)O)c2)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.63
▸ KLKB1 P03952 5/20 0.52
▸ NPSR1 Q6W5P4 3/20 0.51
▸ ALDH1A1 P00352 2/20 0.51
▸ POLB P06746 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ MAPT P10636 1/20 0.50
▸ GPR132 Q9UNW8 1/20 0.49
▸ AGTR2 P50052 1/20 0.47
▸ TSHR P16473 2/20 0.46
▸ LMNA P02545 2/20 0.46
▸ SCD O00767 1/20 0.46
▸ SCD5 Q86SK9 1/20 0.46
▸ CYP4F2 P78329 2/20 0.45
▸ CYP4A11 Q02928 2/20 0.45
▸ HPGD P15428 2/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15592370 0.89 KDM4E (0.63) KDM4EKLKB1NPSR1ALDH1A1POLB
SCHEMBL19087151 0.82 POLB (0.71) KDM4EKLKB1ALDH1A1POLBTDP1
SCHEMBL15601876 0.82 KLKB1 (0.58) KDM4EKLKB1NPSR1ALDH1A1POLB
SCHEMBL19086984 0.79 CD74 (0.57) KDM4EKLKB1POLBTDP1L3MBTL1
SCHEMBL15601842 0.75 ALPI (0.45) KDM4EKLKB1ALDH1A1POLBMAPT
SCHEMBL15601844 0.75 POLB (0.52) KDM4EKLKB1ALDH1A1POLBTDP1
SCHEMBL15592367 0.73 KDM4E (0.57) KDM4EKLKB1NPSR1ALDH1A1POLB
SCHEMBL18653962 0.72 PDE5A (0.53) GPR132TSHRLMNACYP4F2CYP4A11
SCHEMBL19087148 0.72 POLB (0.68) KDM4ENPSR1ALDH1A1POLBTDP1
SCHEMBL25583758 0.72 ALDH1A1 (0.54) KLKB1NPSR1ALDH1A1POLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9062028-B2 Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2015-06-23 — — US disclosed
US-20140080788-A1 NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2014-03-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140080788-A1 NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS GRK5, GPBAR1, GPR55 KDM4E 1877/4885KLKB1 4622/4885NPSR1 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback